Samjin Pharmaceuticals Co., Ltd.
KSE 005500.KS
Samjin Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 7.66 M
-
Samjin Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 37.26 M, a 21.57% change year over year.
-
Samjin Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 30.65 M, a 815.24% change year over year.
-
Samjin Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -4.29 M, a 53.31% change year over year.
-
Samjin Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD -9.18 M, a 30.01% change year over year.
| Date | Net Cash Used Provided By Financing Activities | Dividends Paid | Capital Expenditure | Effect Of Forex Changes On Cash |
|---|
| CEO | Yong-Joo Choi |
| IPO Date | Sept. 29, 2005 |
| Location | South Korea |
| Headquarters | 121 Wausan Ro |
| Employees | 586 |
| Sector | Health Care |
| Industries | |
Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.
Past 5 years
USD 68.20
USD 3.32
USD 4.37
USD 108.37
USD 7.02
StockViz Staff
January 15, 2025
Any question? Send us an email